Skip to main content

Table 1 Demographic data and clinical characteristics

From: Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B

Characteristic n = 91
Baseline (end of treatment)
 Age, years 35.7 ± 7.9
 Sex (Male: Female) 75:16
 First-line NA therapy a 39 (42%)
 Therapy duration, years 56.7 ± 26.2
 Consolidation therapy duration, months 28 (18–46)
 ALT level, × ULN 0.5 (0.4–0.7)
ALT elevation, n (%)
 < ULN 78 (86%)
 ULN-2 × ULN 12 (13%)
 HBV DNA level, log10 IU/ml UD
 HBsAg level, log10 IU/ml 2.9 (2.3–3.3)
 < 100 IU/ml 20 (22%)
 100–1000 IU/ml 31 (34%)
 > 1000 IU/ml 40 (44%)
Start of treatment
 HBeAg status (Positive: Negative) 61:30
 ALT elevation ×ULN 5.33 ± 4.29
 HBV DNA log10 IU/ml 6.20 ± 1.41
  1. Quantitative variables are expressed as mean values ± standard deviation (range) or median values (range). ALT Alanine aminotransferase, HBsAg Hepatitis B surface antigen, HBV Hepatitis B virus, NA Nucleos(t)ide analogue, UD Undetectable (< 20 IU/ml), ULN Upper limit of normal
  2. aFirst-line: entecavir, tenofovir